Molecular targeting for treatment of human T-lymphotropic virus type 1 infection.
Adult T-cell leukemia-lymphoma (ATLL)
Antiviral therapy
Human T-cell lymphotropic virus 1 (HTLV-1)
Integrase
Protease
Reverse transcriptase
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
13
08
2018
revised:
22
10
2018
accepted:
24
10
2018
entrez:
16
12
2018
pubmed:
16
12
2018
medline:
2
4
2019
Statut:
ppublish
Résumé
Human T-cell lymphotropic virus type 1 (HTLV-1) infection is linked to adult T-cell leukemia-lymphoma (ATLL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and several other disorders. ATLL occurs in approximately 5% of the 15-20 million people infected by HTLV-1 in the world. In general, ATLL is resistant to chemotherapy, which underlines the need for new and effective therapeutic strategies. Previous studies highlighted the role of viral enzymes, responsible for viral replication, and regulatory proteins such as Tax and HBZ in the progression of HTLV-1-associated diseases. There are conflicting reports on the efficacy of current enzyme inhibitors, mainly developed against human immunodeficiency virus (HIV), for treatment of HTLV-1 infection. New treatment approaches including monoclonal antibodies show promising results and exert significant cytotoxic effects on ATLL cells. This manuscript reviews the recent developments in molecular targeting for treatment of HTLV-1 infection.
Identifiants
pubmed: 30551530
pii: S0753-3322(18)35481-7
doi: 10.1016/j.biopha.2018.10.139
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Enzyme Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
770-778Informations de copyright
Copyright © 2018 Elsevier Masson SAS. All rights reserved.